NASDAQ:VIVE - Viveve Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.99 0.00 (0.00 %)
(As of 03/22/2019 04:04 AM ET)
Previous Close$0.9902
Today's Range$0.99 - $1.04
52-Week Range$0.87 - $4.34
Volume234,986 shs
Average Volume179,279 shs
Market Capitalization$31.23 million
P/E Ratio-0.47
Dividend YieldN/A
Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Receive VIVE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:VIVE
Previous SymbolOTCMKTS:PLCSD



Sales & Book Value

Annual Sales$18.52 million
Book Value($0.13) per share


Net Income$-36,950,000.00
Net Margins-266.96%


Market Cap$31.23 million
Next Earnings DateN/A

Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How were Viveve Medical's earnings last quarter?

Viveve Medical Inc (NASDAQ:VIVE) issued its earnings results on Thursday, August, 9th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.01. The business earned $5.53 million during the quarter, compared to the consensus estimate of $4.97 million. Viveve Medical had a negative return on equity of 669.39% and a negative net margin of 266.96%. View Viveve Medical's Earnings History.

What guidance has Viveve Medical issued on next quarter's earnings?

Viveve Medical issued an update on its FY 2019 earnings guidance on Wednesday, January, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $22.2 million.Viveve Medical also updated its FY 2018 guidance to EPS.

What price target have analysts set for VIVE?

5 equities research analysts have issued 1 year price objectives for Viveve Medical's stock. Their predictions range from $1.00 to $6.00. On average, they expect Viveve Medical's stock price to reach $4.00 in the next year. This suggests a possible upside of 304.0% from the stock's current price. View Analyst Price Targets for Viveve Medical.

What is the consensus analysts' recommendation for Viveve Medical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viveve Medical.

What are Wall Street analysts saying about Viveve Medical stock?

Here are some recent quotes from research analysts about Viveve Medical stock:
  • 1. Mizuho analysts commented, "We expect these data readouts and milestone events will be the key drivers of VIVE shares in 2019/2020." (3/15/2019)
  • 2. Maxim Group analysts commented, "Market open, VIVE reported preliminary 4Q18 revenue that was slightly above both our estimate and consensus. However, the company also introduced full-year 2019 revenue guidance that was slightly below both our estimate and consensus. VIVE announced a strategic restructuring that is expected to reduce its workforce by 36% in order to decrease operating costs. Based on its recent capital raise and strategic realignment plan, we believe VIVE has sufficient cash to fund operations through 1Q20. The company plans to report full 4Q18 results in March 2019." (1/17/2019)

Has Viveve Medical been receiving favorable news coverage?

Media stories about VIVE stock have been trending somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Viveve Medical earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near future.

Who are some of Viveve Medical's key competitors?

What other stocks do shareholders of Viveve Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Synergy Pharmaceuticals (SGYP), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Novavax (NVAX), Trevena (TRVN), Genocea Biosciences (GNCA), Verastem (VSTM) and Abeona Therapeutics (ABEO).

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the folowing people:
  • Mr. Scott C. Durbin, CEO & Director (Age 50)
  • Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 61)
  • Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 61)
  • Mr. Jim B. Robbins, VP of Fin. & Admin., Principal Accounting Officer & Principal Financial Officer (Age 55)
  • Mr. Martin Kerber, VP of Operations

When did Viveve Medical IPO?

(VIVE) raised $13 million in an IPO on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.

Who are Viveve Medical's major shareholders?

Viveve Medical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (20.87%), RTW Investments LP (14.21%), Stonepine Capital Management LLC (10.84%), Polar Capital LLP (2.26%), Geode Capital Management LLC (0.69%) and Geode Capital Management LLC (0.69%). View Institutional Ownership Trends for Viveve Medical.

Which major investors are selling Viveve Medical stock?

VIVE stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Polar Capital LLP. View Insider Buying and Selling for Viveve Medical.

Which major investors are buying Viveve Medical stock?

VIVE stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, RTW Investments LP, Bank of New York Mellon Corp, Sargent Investment Group LLC, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Viveve Medical.

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $0.99.

How big of a company is Viveve Medical?

Viveve Medical has a market capitalization of $31.23 million and generates $18.52 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

What is Viveve Medical's official website?

The official website for Viveve Medical is

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]

MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by Staff

Featured Article: Retained Earnings

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel